Welcome To The Mannkind HUB On AGORACOM

Edit this title from the Fast Facts Section

Free
Message: An Excellent BioTech Bet For 2013

And don't forget the runnup to over $10 prior to last pdufa. Shorts would prefer to cover at current prices and then reload on any pre-pdufa runnup. It seems many of the shorts are not afraid of FDA approval; probably becasue they believe Affrezza will ultimately fail from a marketing perspective. I say this because of the volume of shorts going into previous pdufa's.

Share
New Message
Please login to post a reply